Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Conditions
- PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive TumorBreast CancerMetastatic Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT06982521
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- Conditions
- Malignant Neoplasm
- Interventions
- Drug: Megestrol acetate/Medroxyprogesterone acetateDrug: Fludrocortisone/ Fludrocortisone acetateDrug: Dexamethasone/Dexamethasone acetateDrug: Rescue Medications
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 250
- Registration Number
- NCT06979596
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
- Conditions
- HR+/HER2- Advanced/Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT06957379
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 640
- Registration Number
- NCT06954961
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 382
- Registration Number
- NCT06941142
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
- Conditions
- HR+/HER2- Advanced/Metastatic Breast Cancer
- Interventions
- Drug: Placebo for Sirolimus for Injection (Albumin-bound)
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 312
- Registration Number
- NCT06929325
- Locations
- 🇨🇳
Clinical Trials Information Group, Shijiazhuang, Hebei, China
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
- Conditions
- Advanced HR - Positive, HER2 - Negative Breast CancerResistant to (Neo)Adjuvant Endocrine Therapy
- Interventions
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT06856200
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, China
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06764186
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Conditions
- Hormone-receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 92
- Registration Number
- NCT06756932
- Locations
- 🇺🇸
Hoag Memorial Presbyterian, Newport Beach, California, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
SNV4818 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Pikavation Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06736704
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.